Tech Transfer Roundup: UM Ventures' Deal-Making Priority Is Flexibility
Executive Summary
Now providing seed and venture funding for some of its start-ups, University of Maryland's tech transfer has expanded its capabilities in recent years. Plus, our monthly roundup of private/public-sector transactions.
You may also be interested in...
Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
The Busiest Dealmakers Of 2022
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
BioNTech Bolsters Cancer Immunotherapy Ambitions In Pact With Cash-Poor Ryvu
Deal Snapshot: German firm gets license rights to Ryvu’s STING agonist portfolio in addition to collaborating on immunomodulators. Ryvu adds need cash via upfront and equity payments from BioNTech.